Christopher Liu
Stock Analyst at Leerink Partners
(2.82)
# 1,672
Out of 5,140 analysts
9
Total ratings
66.67%
Success rate
35.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Upgrades: Outperform | $48 | $44.81 | +7.12% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $24.12 | -17.08% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $1.69 | +432.54% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $2.83 | +253.36% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $7.54 | +138.73% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $36.01 | -25.02% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $109.04 | -61.48% | 1 | Aug 8, 2023 |
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $44.81
Upside: +7.12%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $24.12
Upside: -17.08%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $1.69
Upside: +432.54%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $2.83
Upside: +253.36%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $7.54
Upside: +138.73%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $36.01
Upside: -25.02%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $109.04
Upside: -61.48%